CTMX
CytomX Therapeutics Inc.
$3.57
+$0.24(+7.21%)
67
Overall
80
Value
81
Tech
42
Quality
Market Cap
$326.53M
Volume
2.77M
52W Range
$0.40 - $3.91
Target Price
$6.14
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $7.7M | $15.0M | $71.6M | $59.5M | $57.5M | $100.4M | $37.3M | $53.2M | $101.2M | $138.1M | ||
| Total Revenue | $7.7M | $12.8M | $71.6M | $59.5M | $57.5M | $100.4M | $37.3M | $53.2M | $101.2M | $138.1M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $7.7M | $15.0M | $71.6M | $59.5M | $57.5M | $100.4M | $37.3M | $53.2M | $101.2M | $138.1M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-40.9M | $-74.6M | $-117.9M | $-137.4M | $168.4M | $149.0M | $153.4M | $154.5M | $107.7M | $113.1M | ||
| Research & Development | $28.4M | $54.8M | $92.3M | $103.9M | $131.6M | $112.9M | $114.2M | $111.6M | $77.7M | $83.4M | ||
| Research Expense | $28.4M | $54.8M | $92.3M | $103.9M | $131.6M | $112.9M | $114.2M | $111.6M | $77.7M | $83.4M | ||
| Selling, General & Administrative | $12.6M | $19.9M | $25.6M | $33.5M | $36.8M | $36.0M | $39.2M | $42.8M | $30.0M | $29.7M | ||
| General & Administrative Expenses | $12.6M | $19.9M | $25.6M | $33.5M | $36.8M | $36.0M | $39.2M | $42.8M | $30.0M | $29.7M | ||
| Salaries & Wages | $-4.0M | $-10.1M | $-11.3M | $-16.9M | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-1.2M | $-1.7M | $-1.5M | $-1.7M | $2.5M | $2.4M | $2.6M | $2.3M | $2.0M | $1.6M | ||
| Depreciation & Amortization | $-1.2M | $-1.7M | $-1.5M | $-1.7M | $2.5M | $2.4M | $2.6M | $2.3M | $2.0M | $1.6M | ||
| Amortization | -- | -- | -- | $-146.0K | $949.0K | $949.0K | $146.0K | $146.0K | $146.0K | $146.0K | ||
| Other Operating Expenses | $2.3M | -- | $-521.0K | $-1.2M | $-1.4M | $-1.2M | $-1.3M | $-1.4M | $-527.0K | $-617.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-33.2M | $-59.6M | $-46.3M | $-77.9M | $-110.9M | $-48.6M | $-116.0M | $-101.3M | $-6.5M | $25.0M | ||
| EBITDA | $-31.2M | $-55.5M | $-41.6M | $-70.1M | $-102.3M | $-78.0M | $-113.3M | $-98.9M | $5.5M | $33.9M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $1.7M | $1.7M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Intinc | $1.3M | $736.0K | $2.7M | $7.6M | $8.4M | $1.8M | $255.0K | $1.7M | $9.8M | $7.1M | ||
| Net Non-Operating Interest Income/Expense | $-417.0K | $736.0K | $2.7M | $7.6M | $8.4M | $1.8M | $255.0K | $1.7M | $9.8M | $7.1M | ||
| Other Income/Expense | $1.7M | $69.0K | $27.0K | $68.0K | $135.0K | $27.0K | $83.0K | $340.0K | $30.0K | $38.0K | ||
| Other Special Charges | $-1.7M | $-69.0K | $-27.0K | $-68.0K | $-135.0K | $-27.0K | $-83.0K | $340.0K | $-30.0K | $-38.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | $7.7M | -- | -- | ||
| Special Income Charges | -- | -- | -- | -- | $11.0K | -- | -- | $-7.7M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-33.6M | $-58.9M | $-43.6M | $-70.3M | $-102.7M | $-80.5M | $-116.0M | $-101.3M | $3.3M | $32.1M | ||
| Pre-Tax Income | $-35.4M | $-58.9M | $-43.6M | $-70.3M | $-102.7M | $-46.8M | $-115.9M | $-99.3M | $3.3M | $32.1M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $10.0K | $-19.0K | $-513.0K | $14.3M | $-427.0K | $-13.9M | -- | -- | $3.9M | $224.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-35.4M | $-58.9M | $-43.1M | $-84.6M | $-102.2M | $-64.8M | $-115.9M | $-99.3M | $-569.0K | $31.9M | ||
| Net Income (Continuing Operations) | $-35.4M | $-58.9M | $-43.1M | $-84.6M | $-102.2M | $-32.9M | $-115.9M | $-99.3M | $-569.0K | $31.9M | ||
| Net Income (Discontinued Operations) | $-35.4M | $-58.9M | $-43.1M | $-84.6M | $-102.2M | $-64.8M | $-115.9M | $-99.3M | $-569.0K | $31.9M | ||
| Net Income (Common Stockholders) | $-42.1M | $-58.9M | $-43.1M | $-84.6M | $-102.2M | $-64.8M | $-115.9M | $-99.3M | $-569.0K | $31.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-91.5M | -- | -- | $31.8M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-40.9M | $-74.6M | $-117.9M | $-137.4M | $168.4M | $149.0M | $153.4M | $154.5M | $107.7M | $113.1M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $8.6M | $36.2M | $37.2M | $41.7M | $45.3M | $46.1M | $64.1M | $65.7M | $73.8M | $84.4M | ||
| Average Shares Outstanding (Diluted) | $7.2M | $36.1M | $37.2M | -- | $45.3M | $46.1M | -- | $65.7M | $73.8M | $84.7M | ||
| Shares Outstanding | $36.1M | $36.5M | $38.6M | $45.1M | $45.6M | $64.8M | $65.4M | $66.2M | $67.7M | $80.1M | ||
| Basic EPS | -- | -- | -- | -- | $-2.26 | $-0.71 | $-1.3 | $-1.51 | $-0.01 | $0.38 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-2.26 | $-0.71 | $-1.3 | $-1.51 | $-0.01 | $0.38 | ||
| Diluted EPS | $-4.9 | $-1.63 | $-1.16 | -- | $-2.26 | $-0.71 | $-1.3 | $-1.51 | $-0.01 | $0.38 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-1.51 | $-0.01 | $0.38 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | $6.7M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Acquired In Process Rn D | -- | -- | -- | -- | $11.0K | -- | -- | -- | -- | -- | ||
| Other Gand A | $12.6M | $19.9M | $25.6M | $33.5M | $36.8M | $36.0M | $39.2M | $42.8M | $30.0M | $29.7M | ||
| Otherunder Preferred Stock Dividend | $6.7M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $6.7M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $12.6M | $19.9M | $25.6M | $33.5M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | $7.7M | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CTMX | $3.57 | +7.2% | 2.77M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get CytomX Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW